With this move, the leading independent company in Spain, backed by Suma Capital, strengthens its presence in the European market by acquiring these two Italian dental sector leaders.
On July 25, 2024, Ziacom Group, a leader in the design, manufacture, and distribution of dental solutions, completed the acquisition of ITS and UBGEN, two Italian companies specializing in biomaterials and dental implants. Both companies, based in Padua, are benchmarks in the oral health sector, particularly in northern Italy. ITS Italy was founded in 2004 by Marco Manno and UBGEN was established in 2013, under the visionary leadership of Marco Manno and Ilenia Geretto. Both companies have been nurtured and developed as a family endeavor. Together, they boast a solid track record and extensive experience in developing innovative and high-quality products for the dental sector.
With this strategic integration, Ziacom Group strengthens its position in the international dental market, expanding its catalog with an innovative line of bovine-derived biomaterials and consolidating its presence in key markets. The acquisition of ITS and UBGEN creates an ideal scenario for generating commercial synergies, leveraging the complementarity of the teams and the expertise of both companies. ITS, with its deep knowledge in niche implantology solutions, will drive Ziacom Group's growth in Italy, while UBGEN, with its extensive experience in biomaterials, membranes, and regenerative solutions, will help expand the group's presence in Europe and globally. This strategic union will allow Ziacom Group to offer a more comprehensive and diversified range of high-quality products and services to dental professionals, reinforcing its commitment to innovation and excellence in the sector.
The recently expanded biomaterial and membrane production facilities will continue to operate in Padua, ensuring continuity and product quality.
This operation not only enriches Ziacom Group's product offerings but also accelerates its geographical expansion in the European and global markets. The retention of ITS and UBGEN's strong commercial networks will enable the group to extend its reach in Southern Europe and other key markets. Additionally, this operation propels Ziacom Group towards a consolidated turnover of 20 million euros, generating significant economies of scale.
With this acquisition, Ziacom Group not only consolidates its leadership in the dental market but also reaffirms its commitment to research and development, thus ensuring its position at the forefront of technological innovation in the sector.
In this regard, Alejandro del Valle, founder and CEO of Ziacom Group, states:
"...These acquisitions strengthen our commitment to offering high-quality products and innovative technologies to our customers. Together, we will be able to accelerate the development of advanced dental solutions and expand our influence, especially in the niche of regenerative solutions, which represent a future promise and revolution in the sector..."
Ziacom Group maintains its growth vision and does not rule out future acquisitions at strategic points, aiming to establish itself as one of the leading manufacturers of comprehensive dental solutions (implants, prosthetics, aligners, biomaterials, and more) in Southern Europe.
Ziacom has been advised by Deloitte and DLA Piper in the Due Diligence and contractual phase, and by Baker Tilly as the main advisor for the operation. The sellers have been assisted by Mr Paolo Penzo as financial advisor and by the law firm DFA.
Suma Capital’s Role
The role of Suma Capital, a leading sustainable and impact investment manager, has been crucial throughout this expansion process, providing not only the necessary financial support but also contributing its strategic expertise to consolidate Ziacom's position in the European market. With their active support, the company has been able to decisively advance its growth strategy, strengthening its presence in new markets and expanding its range of products and services to meet the evolving demands of the dental sector.
Suma Capital entered the shareholding of Ziacom Medical in 2022 with a 40% stake through the SC Growth Fund II, an expansion capital fund with a strong ESG focus.
